Why the CSL (ASX:CSL) share price might be headed for more trouble

The CSL Ltd (ASX: CSL) share price has continued to trade sideways despite the S&P/ASX 200 Index (ASX: XJO) running around 6% higher year to date. 

The ASX 200 is now within 2% of its pre-COVID high, but the CSL share price needs to add another 25% to be in a similar position. After what seemed like strong half-year results back in February, what’s next for the CSL share price? 

CSL share price impacted by plasma collections

Plasma is an essential raw material for CSL Behring’s immunoglobulins, which generated US$4,256 million of the group’s US$5,739 million revenue in the first half of FY21.

The pandemic has adversely affected plasma collections, with December 2020 collection volumes representing ~80% of December 2019…